287 related articles for article (PubMed ID: 33475078)
21. Fibroblast growth factor receptor inhibitor erdafitinib promotes Mcl-1 degradation and synergistically induces apoptosis with Bcl-xL/Bcl-2 inhibitor in urothelial cancer cells.
Ohtsu A; Arai S; Sawada T; Kato M; Maeno Y; Miyazawa Y; Fujizuka Y; Sekine Y; Koike H; Matsui H; Suzuki K
Biochem Biophys Res Commun; 2022 Nov; 628():76-83. PubMed ID: 36084554
[TBL] [Abstract][Full Text] [Related]
22. P4HA2-mediated HIF-1α stabilization promotes erdafitinib-resistance in FGFR3-alteration bladder cancer.
Li X; Li Y; Liu B; Chen L; Lyu F; Zhang P; He Q; Cheng L; Liu C; Song Y; Xing Y
FASEB J; 2023 Apr; 37(4):e22840. PubMed ID: 36943397
[TBL] [Abstract][Full Text] [Related]
23. Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib.
de Almeida Carvalho LM; de Oliveira Sapori Avelar S; Haslam A; Gill J; Prasad V
JAMA Netw Open; 2019 Nov; 2(11):e1916091. PubMed ID: 31755953
[TBL] [Abstract][Full Text] [Related]
24. Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma.
Lyou Y; Grivas P; Rosenberg JE; Hoffman-Censits J; Quinn DI; P Petrylak D; Galsky M; Vaishampayan U; De Giorgi U; Gupta S; Burris H; Rearden J; Li A; Wang H; Reyes M; Moran S; Daneshmand S; Bajorin D; Pal SK
Eur Urol; 2020 Dec; 78(6):916-924. PubMed ID: 32847703
[TBL] [Abstract][Full Text] [Related]
25. Re: Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
Tilgener C; Bedke J
Eur Urol; 2024 Jun; 85(6):591-592. PubMed ID: 38538421
[No Abstract] [Full Text] [Related]
26. Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib.
Karkera JD; Cardona GM; Bell K; Gaffney D; Portale JC; Santiago-Walker A; Moy CH; King P; Sharp M; Bahleda R; Luo FR; Alvarez JD; Lorenzi MV; Platero SJ
Mol Cancer Ther; 2017 Aug; 16(8):1717-1726. PubMed ID: 28416604
[TBL] [Abstract][Full Text] [Related]
27. Biomarker-Oriented Therapy in Bladder and Renal Cancer.
Scholtes MP; Alberts AR; Iflé IG; Verhagen PCMS; van der Veldt AAM; Zuiverloon TCM
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799514
[TBL] [Abstract][Full Text] [Related]
28. Adipocyte Precursor-Derived NRG1 Promotes Resistance to FGFR Inhibition in Urothelial Carcinoma.
Hosni S; Kilian V; Klümper N; Gabbia D; Sieckmann K; Corvino D; Winkler A; Saponaro M; Wörsdörfer K; Schmidt D; Hahn O; Zanotto I; Bertlich M; Toma M; Bald T; Eckstein M; Hölzel M; Geyer M; Ritter M; Wachten D; De Martin S; Alajati A
Cancer Res; 2024 Mar; 84(5):725-740. PubMed ID: 38175774
[TBL] [Abstract][Full Text] [Related]
29. FGFR inhibition augments anti-PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression.
Okato A; Utsumi T; Ranieri M; Zheng X; Zhou M; Pereira LD; Chen T; Kita Y; Wu D; Hyun H; Lee H; Gdowski AS; Raupp JD; Clark-Garvey S; Manocha U; Chafitz A; Sherman F; Stephens J; Rose TL; Milowsky MI; Wobker SE; Serody JS; Damrauer JS; Wong KK; Kim WY
J Clin Invest; 2024 Jan; 134(2):. PubMed ID: 38226620
[TBL] [Abstract][Full Text] [Related]
30. Salvage systemic therapy for metastatic urothelial carcinoma: an unmet clinical need.
Montazeri K; Sonpavde G
Expert Rev Anticancer Ther; 2021 Mar; 21(3):299-313. PubMed ID: 33249937
[TBL] [Abstract][Full Text] [Related]
31. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
Loriot Y; Necchi A; Park SH; Garcia-Donas J; Huddart R; Burgess E; Fleming M; Rezazadeh A; Mellado B; Varlamov S; Joshi M; Duran I; Tagawa ST; Zakharia Y; Zhong B; Stuyckens K; Santiago-Walker A; De Porre P; O'Hagan A; Avadhani A; Siefker-Radtke AO;
N Engl J Med; 2019 Jul; 381(4):338-348. PubMed ID: 31340094
[TBL] [Abstract][Full Text] [Related]
32. Erdafitinib for the treatment of urothelial cancer.
Marandino L; Raggi D; Giannatempo P; Farè E; Necchi A
Expert Rev Anticancer Ther; 2019 Oct; 19(10):835-846. PubMed ID: 31544541
[No Abstract] [Full Text] [Related]
33. Targeting the FGFR Pathway in Urothelial Carcinoma: the Future Is Now.
Peng J; Sridhar S; Siefker-Radtke AO; Selvarajah S; Jiang DM
Curr Treat Options Oncol; 2022 Sep; 23(9):1269-1287. PubMed ID: 35962938
[TBL] [Abstract][Full Text] [Related]
34. Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer.
Weickhardt AJ; Lau DK; Hodgson-Garms M; Lavis A; Jenkins LJ; Vukelic N; Ioannidis P; Luk IY; Mariadason JM
BMC Cancer; 2022 May; 22(1):478. PubMed ID: 35501832
[TBL] [Abstract][Full Text] [Related]
35. A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality.
Jain NK; Tailang M; Thangavel N; Makeen HA; Albratty M; Najmi A; Alhazmi HA; Zoghebi K; Alagusundaram M; Jain HK; Chandrasekaran B
Acta Pharm; 2024 Mar; 74(1):1-36. PubMed ID: 38554385
[TBL] [Abstract][Full Text] [Related]
36. Erdafitinib in the Treatment of Metastatic Urothelial Carcinoma.
Castro-Alonso FJ; Beas-Lozano E; Remolina-Bonilla YA; Flaig TW; Bourlon MT
Oncology (Williston Park); 2023 Jun; 37(6):256-261. PubMed ID: 37343207
[TBL] [Abstract][Full Text] [Related]
37. The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor.
Morales-Barrera R; Suárez C; González M; Valverde C; Serra E; Mateo J; Raventos C; Maldonado X; Morote J; Carles J
Cancer Treat Rev; 2020 Jun; 86():102000. PubMed ID: 32203842
[TBL] [Abstract][Full Text] [Related]
38. Exposure-response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma.
Dosne AG; Valade E; Goeyvaerts N; De Porre P; Avadhani A; O'Hagan A; Li LY; Ouellet D; Perez Ruixo JJ
Cancer Chemother Pharmacol; 2022 Feb; 89(2):151-164. PubMed ID: 34977972
[TBL] [Abstract][Full Text] [Related]
39. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.
Lamont FR; Tomlinson DC; Cooper PA; Shnyder SD; Chester JD; Knowles MA
Br J Cancer; 2011 Jan; 104(1):75-82. PubMed ID: 21119661
[TBL] [Abstract][Full Text] [Related]
40. Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.
Bahleda R; Italiano A; Hierro C; Mita A; Cervantes A; Chan N; Awad M; Calvo E; Moreno V; Govindan R; Spira A; Gonzalez M; Zhong B; Santiago-Walker A; Poggesi I; Parekh T; Xie H; Infante J; Tabernero J
Clin Cancer Res; 2019 Aug; 25(16):4888-4897. PubMed ID: 31088831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
